CIViC Compass
Research use only — not FDA-cleared, not medical advice. Always consult FDA-approved labeling and a qualified clinician.

CIViC Evidence Items

48 evidence items indexed

Evidence Level Distribution

CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).

AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale

Gene × Evidence Type

Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.

PredictiveDiagnosticPrognosticFunctionalPredispos.Oncogenic
BCR::ABL132311
BRAF18642621
EGFR2481232
EML4::ALK64
ERBB21422
FLT355221
KIT10237
KRAS1594244
PIK3CA156164
PTEN5313121
TP5352401002
VHL52363515
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
Clear
LevelGeneVariantTypeDirectionSignificanceDiseaseDrugsSource
BNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaBinimetinibDummer et al., 2017
BNRASQ61PredictiveSupportsResistanceMelanomaVemurafenibTrunzer et al., 2013
BNRASMutationPrognosticSupportsMultiple MyelomaChng et al., 2008
DNRASMutationPredictiveSupportsSensitivity/ResponseMelanomaTrametinib,OmipalisibPosch et al., 2013
BNRASG12/G13PrognosticSupportsPoor OutcomeAcute Myeloid LeukemiaPapaemmanuil et al., 2016
ANRASMutationPredictiveSupportsResistanceColorectal CancerCetuximab,PanitumumabBenson et al., 2017
BNRASQ61DiagnosticSupportsPositiveMelanomaTschandl et al., 2013
BNRASMutationPrognosticSupportsPoor OutcomeColorectal CancerTherkildsen et al., 2014
BNRASMutationPrognosticDoes Not SupportAcute Myeloid LeukemiaBowen et al., 2005
BNRASG12PrognosticDoes Not SupportAcute Myeloid LeukemiaBacher et al., 2006
BNRASMutationPrognosticSupportsPoor OutcomeMelanomaJakob et al., 2012
BNRASQ61PredictiveDoes Not SupportResistanceColorectal CancerCetuximabDe Roock et al., 2010
BNRASQ61PrognosticSupportsFollicular Thyroid CarcinomaFukahori et al., 2012
DNRASQ61KPredictiveSupportsSensitivity/ResponseNeuroblastomaBinimetinib,EverolimusKiessling et al., 2016
DNRASMutationPredictiveSupportsSensitivity/ResponseCancerMetformin,TrametinibVujic et al., 2015
DNRASMutationPredictiveSupportsSensitivity/ResponseMelanomaBinimetinibThumar et al., 2014
CNRASG12DPredictiveSupportsResistanceColorectal CancerCetuximab,IrinotecanDe Roock et al., 2010
CNRASQ61LPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CNRASQ61KPredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
DNRASQ61KPredictiveSupportsSensitivity/ResponseColorectal CancerDactolisib,SelumetinibMigliardi et al., 2012
BNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaBinimetinib,RibociclibVu et al., 2016
CNRASG12CPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
BNRASMutationPredictiveDoes Not SupportSensitivity/ResponseSolid TumorBinimetinibCleary et al., 2021
CNRASG13DPredictiveSupportsSensitivity/ResponseMelanomaTanespimycinBanerji et al., 2008
CNRASQ61LPredictiveSupportsSensitivity/ResponseMelanomaTemozolomideSoon et al., 2011
CNRASQ61RPredictiveSupportsSensitivity/ResponseMelanomaTemozolomideSoon et al., 2011
BNRASQ61PredictiveSupportsResistanceColorectal CancerCetuximab,ChemotherapyDe Roock et al., 2010
CNRASMutationPredictiveDoes Not SupportResistanceMelanomaMEK Inhibitor RO4987655Zimmer et al., 2014
BNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaTrametinib,DocetaxelCoupe et al., 2015
BNRASQ61PredictiveSupportsSensitivity/ResponseSkin MelanomaBinimetinibAscierto et al., 2013
BNRASMutationPredictiveDoes Not SupportSensitivity/ResponseMelanomaTrametinibFalchook et al., 2012
BNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaBinimetinibAscierto et al., 2013
CNRASQ61PredictiveSupportsSensitivity/ResponseSkin MelanomaSelumetinibAdjei et al., 2008
DNRASQ61KPredictiveSupportsResistanceSkin MelanomaVemurafenibAtefi et al., 2011
DNRASQ61KPredictiveSupportsSensitivity/ResponseSkin MelanomaSelumetinibAtefi et al., 2011
DNRASMutationPredictiveSupportsResistanceColorectal CancerCetuximabBertotti et al., 2011
CNRASQ61RPredictiveSupportsResistanceColorectal CancerCetuximabDe Roock et al., 2010
BNRASMutationPredictiveSupportsResistanceColorectal CancerChemotherapy,CetuximabDe Roock et al., 2010
DNRASQ61KPredictiveSupportsSensitivity/ResponseLung Non-small Cell CarcinomaSelumetinib,TrametinibOhashi et al., 2013
CNRASQ61HPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
BNRASMutationPredictiveSupportsResistanceMelanomaVemurafenib,DabrafenibShi et al., 2014
BNRASQ61PrognosticDoes Not SupportPoor OutcomeFollicular Thyroid CarcinomaMuzza et al., 2015
CNRASQ61KPredictiveSupportsSensitivity/ResponseOvary Serous AdenocarcinomaTrametinibChamper et al., 2019
DNRASMutationPredictiveSupportsSensitivity/ResponseSkin MelanomaAmuvatinibFedorenko et al., 2014
CNRASG13RPredictiveSupportsResistanceColorectal CancerIrinotecan,CetuximabDe Roock et al., 2010
CNRASG13RPredictiveSupportsResistanceColorectal CancerPanitumumabDe Roock et al., 2010
BNRASG12DPredictiveSupportsResistanceColorectal CancerCetuximabKaczirek et al., 2015
BNRASQ179*PredictiveSupportsResistanceColorectal CancerCetuximabKaczirek et al., 2015